Loading
A phase 3 trial of Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT04765059 by AstraZeneca, with 98 participants enrolled, started 2021-09-12 and due to reach its primary completion in 2024-10-28. Interventions recorded: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin. Conditions listed: Non-small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
98 enrolled.
95% CI 5.75 to 11.83; Figures from the ClinicalTrials.gov results section (first posted 2026-01-13), not from a publication · 95% CI 3.52 to 5.55
Source95% CI 12.39 to 20.83; Figures from the ClinicalTrials.gov results section (first posted 2026-01-13), not from a publication · 95% CI 8.38 to 17.25
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS)primary | Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin | 49 | 8.4 months | 0.43 (0.27 to 0.7) | - | link |
| Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin | 49 | 4.4 months | ||||
| Overall Survival (OS) | Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin | 49 | 15.9 months | 0.71 (0.42 to 1.23) | - | link |
| Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin | 49 | 9.8 months |
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.